SANGAMO THERAPEUTICS, INC (SGMO) Form 8-K — Sep 21, 2026
$SGMOForm 8-KItems 1.03, 2.01, 9.01Filed Sep 21, 2026, 4:01 PM ET0001193125-26-396644Original filing
Sangamo Therapeutics completed the sale of substantially all of its assets — primarily ST-920 (isaralgagene civaparvovec), its one-time AAV gene therapy for Fabry disease — to PTC Therapeutics on September 17, 2026. Total consideration is $111 million in cash at closing plus up to an additional $100 million in contingent milestone payments, along with PTC's assumption of certain specified liabilities. The sale closed under Sangamo's Chapter 11 case (Case No. 26-10989 in the District of Delaware), which the company filed on June 23, 2026.
Key figures
- Deal Value Usd
- $111,000,000 cash at closing plus up to $100,000,000 in contingent milestone consideration
- Auction Date
- 2026-08-10
- Sale Order Date
- 2026-09-02
- Sale Closing Date
- 2026-09-17
- Current Otc Symbol
- SGMOQ
- Chapter11 Filing Date
- 2026-06-23
- Bankruptcy Case Number
- 26-10989
- Delisting Effective Date
- 2026-09-27
- Asset Purchase Agreement Date
- 2026-08-25
- Cash Consideration At Closing
- 111000000
- Max Contingent Milestone Consideration
- 100000000
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.